Efficacy of Intravenous Tissue-type Plasminogen Activator on Acute Ischemic Stroke Patients With Large Vessel Occlusions

NCT04170647 | Unknown

• 1 other identifier: UMP11192019
• Study Type: observational
• Target: 81
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational prospective study about the reperfusion rate of intravenous thrombolysis on ischemic stroke patients with large vessel occlusions and predictor factors of successful recanalization.

Conditions

Stroke, Ischemic; Stroke, Acute

Keywords

reperfusion; IVT

Outcome Measures

Primary Outcomes (1)

• reperfusion rate

  the reperfusion rate of intravenous thrombolysis in acute ischemic stroke with large vessel occlusion first confirmed by angiography and assessed later by a vascular imaging modality.

  within 24 hours of hospitalization

Secondary Outcomes (1)

• symptomatic intracerebral hemorrhage

  48 hours after initiation of IVT

Interventions

Plasminogen Activators DRUG

standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Acute ischemic stroke patients presented at our hospital with LVO confirmed who received both intravenous tissue-type plasminogen activator and subsequent repeat angiography will be included in our study.

You may qualify if:

• Age 18 and older with consent form signed.
• Patients hospitalized in 115 People's Hospital for acute ischemic stroke.
• Patients receiving full dose of IVT, with a confirmed LVO (including MCA M1, MCA M2, ICA, BA and VA) on angiography and repeat vascular imaging within 24 hours of hospitalization.

You may not qualify if:

• Patients with evidence of chronic occlusion of large vessels.
• Patients without source angiography data to assess the characteristics of thrombus

Sponsors & Collaborators

• University of Medicine and Pharmacy at Ho Chi Minh City: lead

Study Sites (1)

115 People's Hospital

Ho Chi Minh City, 700000, Vietnam

RECRUITING

MeSH Terms

Conditions

Ischemic Stroke; Stroke

Interventions

Plasminogen Activators

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Serine Endopeptidases; Endopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Serine Proteases; Blood Coagulation Factors; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins

Central Study Contacts

TINH Dang Quang, MD

CONTACT

0084 783629421; tinh942008@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: November 18, 2019
• First Posted: November 20, 2019
• Study Start: October 1, 2017
• Primary Completion: January 1, 2020
• Study Completion: January 1, 2020
• Last Updated: November 20, 2019

Record last verified: 2019-11

Locations

VN (1)